Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $20 to $21.
Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $20 to $21.